|
1
|
Lynch JP III, Derhovanessian A, Tazelaar H
and Belperio JA: Granulomatosis with polyangiitis (wegener's
granulomatosis): Evolving concepts in treatment. Semin Respir Crit
Care Med. 39:434–458. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lane SE, Watts R and Scott DG:
Epidemiology of systemic vasculitis. Curr Rheumatol Rep. 7:270–275.
2005.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Seo P and Stone JH: The antineutrophil
cytoplasmic antibody-associated vasculitides. Am J Med. 117:39–50.
2004.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Iijima Y, Kobayashi Y, Uchida Y, Tsutsui
T, Kakizaki Y, Naganuma T, Tsukamoto K, Oyama T and Miyashita Y: A
case report of granulomatous polyangiitis complicated by
tuberculous lymphadenitis. Medicine (Baltimore).
97(e12430)2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Emamikhah M, Sina F, Mokhtari M, Shirani F
and Asadipanah M: Wegener's granulomatosis presenting as wallenberg
syndrome: A case report. J Stroke Cerebrovas Dis.
28(e107-e109)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Cartin-Ceba R, Peikert T and Specks U:
Pathogenesis of ANCA-associated vasculitis. Curr Rheumatol Rep.
14:481–493. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lutalo PM and D'Cruz DP: Diagnosis and
classification of granulomatosis with polyangiitis (aka Wegener's
granulomatosis). J Autoimmun. 48-49:94–98. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Rao JK, Allen NB, Feussner JR and
Weinberger M: A prospective study of antineutrophil cytoplasmic
antibody (c-ANCA) and clinical criteria in diagnosing Wegener's
granulomatosis. Lancet. 346:926–931. 1995.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bonaci-Nikolic B, Andrejevic S, Bukilica M
and Nikolic MM: Clinical and prognostic value of antineutrophil
cytoplasmic antibodies in Wegener's granulomatosis and microscopic
polyangiitis: Comment on the article by Russell et al.
Arthritis Rheum. 46:278–280. 2002.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sharma A, MB A, Naidu S, Rathi M, Pinto B,
Dhir V, Verma R, Sharma K, Nada R, Jain S, et al: Validation of the
ACR EULAR provisional 2017 classification criteria of
granulomatosis with polyangiitis (GPA) amongst patients with ANCA
associated vasculitis [abstract]. Arthritis Rheumato. 69
(Suppl):2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Merkel PA, Xie G, Monach PA, Ji X,
Ciavatta DJ, Byun J, Pinder BD, Zhao A, Zhang J, Tadesse Y, et al:
Identification of functional and expression polymorphisms
associated with risk for antineutrophil cytoplasmic
autoantibody-associated vasculitis. Arthritis Rheum. 69:1054–1066.
2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gao Y and Zhao MH: Review article:
Drug-induced anti-neutrophil cytoplasmic antibody-associated
vasculitis. Nephrol (Carlton). 14:33–41. 2009.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Mahr AD, Neogi T, Lavalley MP, Davis JC,
Hoffman GS, McCune WJ, Specks U, Spiera RF, St Clair EW, Stone JH,
et al: Assessment of the item selection and weighting in the
Birmingham vasculitis activity score for Wegener's granulomatosis.
Arthritis Rheum. 59:884–891. 2008.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mukhtyar C, Guillevin L, Cid MC, Dasgupta
B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg
CG, et al: EULAR recommendations for the management of primary
small and medium vessel vasculitis. Ann Rheum Dis. 68:310–317.
2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Polychronopoulos VS, Prakash UB, Golbin
JM, Edell ES and Specks U: Airway involvement in Wegener's
granulomatosis. Rheum Dis Clin North Am. 33:755–775.
2007.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Almouhawis HA, Leao JC, Fedele S and
Porter SR: Wegener's granulomatosis: A review of clinical features
and an update in diagnosis and treatment. J Oral Pathol Med.
42:507–516. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cadoni G, Prelajade D, Campobasso E, Calŏ
L, Agostino S, Manna R and Paludetti G: Wegener's granulomatosis: A
challenging disease for otorhinolaryngologists. Acta Otolaryngol.
125:1105–1110. 2005.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Semple D, Keogh J, Forni L and Venn R:
Clinical review: Vasculitis on the intensive care unit-part 2:
Treatment and prognosis. Crit Care. 9:193–197. 2005.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Heijl C, Westman K, Höglund P and Mohammad
AJ: Malignancies in patients with ANCA-associated vasculitis-A
population based cohort study. J Rheumatol.
pii(jrheum.181438)2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Nagasaka K, Harigai M, Hagino N, Hara A,
Horita T, Hayashi T, Itabashi M, Ito S, Katsumata Y, Kawashima S,
et al: Systematic review and meta-analysis for 2017 clinical
practice guidelines of the Japan research committee of the ministry
of health, labour, and welfare for intractable vasculitis for the
management of ANCA-associated vasculitis. Mod Rheumatol.
29:119–129. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Peters JE, Salama AD and Ind PW: Wegener's
granulomatosis presenting as acute systemic vasculitis following 20
years of limited tracheobronchial disease. J Laryngol Otol.
123:1375–1377. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Heijl C, Mohammad AJ, Westman K and
Hoglund P: Long-term patient survival in a Swedish population-based
cohort of patients with ANCA-associated vasculitis. RMD Open.
3(e000435)2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
von Borstel A, Land J, Abdulahad WH,
Rutgers A, Stegeman CA, Diepstra A, Heeringa P and Sanders JS:
CD27(+)CD38(hi) B cell frequency during remission predicts
relapsing disease in granulomatosis with polyangiitis patients.
Front Immunol. 10(2221)2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Cosano Povedano A, Munoz Cabrera L, Cosano
Povedano FJ, Rubio Sanchez J, Pascual Martinez N and Escribano
Duenas A: Endoscopic treatment of central airway stenosis: Five
years' experience. Arch Bronconeumol(Spanish). 41:322–327.
2005.PubMed/NCBI View Article : Google Scholar
|
|
25
|
McClure M, Gopaluni S, Jayne D and Jones
R: B cell therapy in ANCA-associated vasculitis: Current and
emerging treatment options. Nat Rev Rheumatol. 14:580–591.
2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Bekker P, Dairaghi D, Seitz L, Leleti M,
Wang Y, Ertl L, Baumgart T, Shugarts S, Lohr L, Dang T, et al:
Correction: Characterization of pharmacologic and pharmacokinetic
properties of CCX168, a potent and selective orally administered
complement 5a receptor inhibitor, based on preclinical evaluation
and randomized phase 1 clinical study. PLoS One.
14(e0210593)2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Berti A, Cavalli G, Campochiaro C,
Guglielmi B, Baldissera E, Cappio S, Sabbadini MG, Doglioni C and
Dagna L: Interleukin-6 in ANCA-associated vasculitis: Rationale for
successful treatment with tocilizumab. Semin Arthritis Rheum.
45:48–54. 2015.PubMed/NCBI View Article : Google Scholar
|
